Helen Grant - Alert Sample

Alert Sample

View the Parallel Parliament page for Helen Grant

Information between 28th November 2025 - 18th December 2025

Note: This sample does not contain the most recent 2 weeks of information. Up to date samples can only be viewed by Subscribers.
Click here to view Subscription options.

Division Votes
2 Dec 2025 - Budget Resolutions - View Vote Context Helen Grant voted No - in line with the party majority and against the House One of 88 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 357 Noes - 174
2 Dec 2025 - Budget Resolutions - View Vote Context Helen Grant voted No - in line with the party majority and against the House One of 89 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 364 Noes - 167
2 Dec 2025 - Budget Resolutions - View Vote Context Helen Grant voted No - in line with the party majority and against the House One of 89 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 362 Noes - 164
2 Dec 2025 - Budget Resolutions - View Vote Context Helen Grant voted No - in line with the party majority and against the House One of 89 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 348 Noes - 176
2 Dec 2025 - Budget Resolutions - View Vote Context Helen Grant voted No - in line with the party majority and against the House One of 90 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 369 Noes - 166
2 Dec 2025 - Budget Resolutions - View Vote Context Helen Grant voted No - in line with the party majority and against the House One of 90 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 327 Noes - 182
2 Dec 2025 - Budget Resolutions - View Vote Context Helen Grant voted No - in line with the party majority and against the House One of 92 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 371 Noes - 166
3 Dec 2025 - Pension Schemes Bill - View Vote Context Helen Grant voted Aye - in line with the party majority and against the House One of 74 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 143 Noes - 304
3 Dec 2025 - Pension Schemes Bill - View Vote Context Helen Grant voted Aye - in line with the party majority and against the House One of 75 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 154 Noes - 303
8 Dec 2025 - Employment Rights Bill - View Vote Context Helen Grant voted No - in line with the party majority and against the House One of 84 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 327 Noes - 162
8 Dec 2025 - Employment Rights Bill - View Vote Context Helen Grant voted No - in line with the party majority and against the House One of 87 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 326 Noes - 162
9 Dec 2025 - Railways Bill - View Vote Context Helen Grant voted Aye - in line with the party majority and against the House One of 95 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 170 Noes - 332
9 Dec 2025 - UK-EU Customs Union (Duty to Negotiate) - View Vote Context Helen Grant voted No - in line with the party majority and in line with the House One of 89 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 100 Noes - 100
9 Dec 2025 - Railways Bill - View Vote Context Helen Grant voted No - in line with the party majority and against the House One of 94 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 329 Noes - 173
10 Dec 2025 - Conduct of the Chancellor of the Exchequer - View Vote Context Helen Grant voted Aye - in line with the party majority and against the House One of 86 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 90 Noes - 297
10 Dec 2025 - Seasonal Work - View Vote Context Helen Grant voted No - in line with the party majority and against the House One of 91 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 320 Noes - 98
10 Dec 2025 - Seasonal Work - View Vote Context Helen Grant voted Aye - in line with the party majority and against the House One of 91 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 98 Noes - 325
15 Dec 2025 - Employment Rights Bill - View Vote Context Helen Grant voted No - in line with the party majority and against the House One of 88 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 311 Noes - 96
16 Dec 2025 - Finance (No. 2) Bill - View Vote Context Helen Grant voted No - in line with the party majority and against the House One of 103 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 341 Noes - 195
16 Dec 2025 - Finance (No. 2) Bill - View Vote Context Helen Grant voted Aye - in line with the party majority and against the House One of 103 Conservative Aye votes vs 0 Conservative No votes Tally: Ayes - 118 Noes - 340
17 Dec 2025 - National Insurance Contributions (Employer Pensions Contributions) Bill - View Vote Context Helen Grant voted No - in line with the party majority and against the House One of 91 Conservative No votes vs 0 Conservative Aye votes Tally: Ayes - 312 Noes - 165

Written Answers
Rare Diseases: Gene Therapies Asked by: Helen Grant (Conservative - Maidstone and Malling) Wednesday 17th December 2025 Question to the Department of Health and Social Care: To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) support the development of treatments for Huntington's disease and (b) improve the ability of the NHS to deliver new gene therapies for people living with rare diseases. Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care) We recognise the significant challenges faced by those living with rare diseases such as Huntington’s Disease. The Department supports research into Huntington’s disease through the National Institute for Health and Care Research (NIHR). NIHR infrastructure supports pioneering research into Huntington's, including the positive preliminary results for a novel gene therapy reported this year. NHS England will assess the service delivery impact of any specific gene therapy for Huntingdon's disease within three years of its expected licensing decision by the Medicines and Healthcare products Regulatory Agency. The National Institute for Health and Care Excellence (NICE) will make recommendations for the National Health Service on new medicines based on clinical and cost effectiveness. NHS England is required to fund medicines recommended by NICE, within three months of the publication of final guidance. The NHS has a dedicated team to support the adoption of advanced therapy medicinal products (ATMPs) that are recommended by NICE. NHS England works with a variety of internal and external stakeholders to ensure timely patient access to ATMPs that are on NICE’s technology appraisal and highly specialised technology workplan.

Written Answers

Rare Diseases: Gene Therapies
Asked by: Helen Grant (Conservative - Maidstone and Malling)
Wednesday 17th December 2025

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) support the development of treatments for Huntington's disease and (b) improve the ability of the NHS to deliver new gene therapies for people living with rare diseases.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

We recognise the significant challenges faced by those living with rare diseases such as Huntington’s Disease. The Department supports research into Huntington’s disease through the National Institute for Health and Care Research (NIHR). NIHR infrastructure supports pioneering research into Huntington's, including the positive preliminary results for a novel gene therapy reported this year. NHS England will assess the service delivery impact of any specific gene therapy for Huntingdon's disease within three years of its expected licensing decision by the Medicines and Healthcare products Regulatory Agency. The National Institute for Health and Care Excellence (NICE) will make recommendations for the National Health Service on new medicines based on clinical and cost effectiveness. NHS England is required to fund medicines recommended by NICE, within three months of the publication of final guidance. The NHS has a dedicated team to support the adoption of advanced therapy medicinal products (ATMPs) that are recommended by NICE. NHS England works with a variety of internal and external stakeholders to ensure timely patient access to ATMPs that are on NICE’s technology appraisal and highly specialised technology workplan.

Helen Grant mentioned

Live Transcript
Note: Cited speaker in live transcript data may not always be accurate. Check video link to confirm.
18 Dec 2025, 10:31 a.m. - House of Commons "I'll now do is move on to Helen Grant. The shadow Solicitor General. >> Well. >> Thank you very. >> Much, Mr. Speaker. " Barry Gardiner MP (Brent West, Labour) - View Video - View Transcript
18 Dec 2025, 10:33 a.m. - House of Commons " Helen Grant I'm not too sure that answered my question, but I shall also have another go this shall also have another go this month. The right hon. Lady's colleague, the Member for Kingston " Helen Grant MP (Maidstone and Malling, Conservative) - View Video - View Transcript